---
document_datetime: 2023-11-09 19:33:37
document_pages: 21
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cometriq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: cometriq-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 12.3880021
conversion_datetime: 2025-12-18 22:58:00.83242
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Cometriq

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                      |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0053              | Update of section 4.8 of the SmPC in order to add embolism arterial to the list of adverse drug reactions (ADRs) with frequency Uncommon based on literature search. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives | 14/09/2023                          |                                             | SmPC and PL                      | Based on safety data collected in the post-marketing setting, section 4.8 of the SmPC has been updated to add embolism arterial with frequency Uncommon to the list of ADRs. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |              |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------|
| IA/0054/G | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.II.c.3.a.1 - Change in source of an excipient or TSE risk - From TSE risk material to | 06/06/2023 | n/a | reagent with |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| reagents NOT used in biol/immunol AS or in product B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material) B.III.1.b.4 - Submission deletion of Ph. Eur. TSE Deletion of certificates exist per material)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                       |            |     | deletion of Ph.   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| IA/0055   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                       | 01/06/2023 | n/a |                   |
| IA/0052/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS | 10/01/2023 | n/a |                   |

<div style=\"page-break-after: always\"></div>

| IA/0051/G           | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                               | 19/12/2022   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10180 /202111 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/07/2022   | 26/09/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/202111.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0049             | Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on hypertension and add hypertensive crisis to the list of adverse drug reactions (ADRs) with frequency not known based on literature review and post-marketing and clinical data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 31/03/2022   | 26/09/2022 | SmPC and PL | SmPC new text Hypertension, including hypertensive crisis, has been observed with cabozantinib. Blood pressure should be well- controlled prior to initiating cabozantinib. After cabozantinib initiation blood pressure should be monitored early and regularly and treated as needed with appropriate anti- hypertensive therapy. In the case of persistent hypertension despite use of anti-hypertensives, the cabozantinib treatment should be interrupted until blood pressure is controlled, after which cabozantinib can be resumed at a reduced dose. Cabozantinib should be discontinued if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of cabozantinib. In case of hypertensive crisis, cabozantinib should be discontinued. |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                                  | For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0048 | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/12/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0044 | Update of section 5.1 of the SmPC based on the final results from study XL184-401 (EXAMINER) (SOB 001), a randomised, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients and as a consequence update of annex II in order to delete SOB 001. With the fulfilment of SOB 001 the MAH is requesting for the Cometriq MA to no longer be subject to specific obligations. The package leaflet is updated accordingly. The updated RMP version 5.5 has also been submitted. Furthermore, information on hepatotoxicity has been added to the section 4.4 and the cross reference between sections 4.1 and 4.4 has been removed for consistency. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated | 22/07/2021 | 16/09/2021 | SmPC, Annex II, Labelling and PL | Update of section 5.1 of the SmPC based on the final results from study XL184-401 (EXAMINER) (SOB 001), a randomised, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients and as a consequence update of annex II in order to delete SOB 001. With the fulfilment of SOB 001 the MAH is requesting for the Cometriq MA to no longer be subject to specific obligations. The package leaflet is updated accordingly. The updated RMP version 5.5 has also been submitted. Furthermore, information on hepatotoxicity has been added to the section 4.4 and the cross reference between sections 4.1 and 4.4 has been removed for consistency. |

<div style=\"page-break-after: always\"></div>

| WS/2104     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/09/2021   | n/a        |                 | manufacturing sites   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-----------------------|
| IA/0047/G   | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 09/08/2021   | n/a        |                 | manufacturing sites   |
| IAIN/0045/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch | 17/05/2021   | 12/08/2021 | Annex II and PL |                       |

<div style=\"page-break-after: always\"></div>

|           | control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                          |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0043/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                             | 04/03/2021 | 12/08/2021 | SmPC, Annex II and PL            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0042    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                    | 10/12/2020 | 11/02/2021 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| IA/0041/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process | 16/10/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure   |            |            |                        |                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0040/G | This was an application for a group of variations. B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                        | 12/10/2020 | n/a        |                        |                                                                                                                                                             |
| II/0036   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                     | 02/07/2020 | n/a        |                        |                                                                                                                                                             |
| IB/0039   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                     | 26/06/2020 | 11/02/2021 | Annex II               |                                                                                                                                                             |
| II/0035   | Update of section 4.2 to introduce a clarification in alignment with Cabometyx; update of section 4.4 of the SmPC to include the addition of the risk of                                                                                                                                                                                                                          | 30/04/2020 | 11/02/2021 | SmPC, Labelling and PL | COMETRIQ (cabozantinib) capsules and CABOMETYX (cabozantinib) tablets are not bioequivalent and should not be used interchangeably. The recommended dose of |

<div style=\"page-break-after: always\"></div>

| diarrhoea and additional text to the existing risks of thromboembolic events, haemorrhage, wound complications and Posterior reversible encephalopathy syndrome (PRES). Update of Section 4.8 of the SmPC, based on the Company Core Safety Information, to add DVT (Deep vein thrombosis) to the existing ADR venous thrombosis in order to alert prescribers to the most frequently reported type of venous thrombosis. Changes to the frequency categorisation of some ADRs are also proposed based on new pooled data. The Package Leaflet is updated accordingly. The MAH took the opportunity to align the product Information with the QRDv10.1 and update the local representative information of Hungary. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   | COMETRIQ is 140 mg once daily, taken as one 80 mg orange capsule and three 20 mg grey capsules. Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. It should be expected that a majority of patients treated with COMETRIQ will require one or more dose adjustments (reduction and/or interruption) due to toxicity. Patients should therefore be closely monitored during the first eight weeks of therapy Events of venous thromboembolism, including pulmonary embolism and events of arterial thromboembolism, sometimes fatal, have been observed with cabozantinib. Cabozantinib should be used with caution in patients who are at risk for, or who have a history of, these events. Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication. Severe haemorrhage, sometimes fatal, has been observed with cabozantinib. Patients who have evidence of involvement of the trachea or bronchi by tumour or a history of haemoptysis prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy. Cabozantinib should not be administered to patients with serious haemorrhage or recent haemoptysis. Diarrhoea, nausea/vomiting, decreased appetite, and stomatitis/oral pain were some of the most commonly reported GI adverse reactions. Prompt medical management, including supportive care with antiemetics, antidiarrhoeals, or antacids, should be instituted to prevent dehydration, electrolyte imbalances and weight loss. Dose interruption or reduction, or permanent discontinuation of   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                              |            |            |                                  | recurrent significant GI adverse reactions. Posterior reversible encephalopathy syndrome (PRES) has been observed with cabozantinib. PRES should be considered in any patient presenting with symptoms suggestive of the diagnosis, including seizures, headache, visual disturbances, confusion or altered mental function. Cabozantinib treatment should be discontinued in patients with PRES.                                                                                  |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0037 | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                          | 23/04/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| IA/0038 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 06/03/2020 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| R/0032  | Renewal of the marketing authorisation.                                                                                                                                                                                                      | 12/12/2019 | 21/02/2020 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| N/0033  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                             | 20/12/2019 | 11/02/2021 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| IAIN/0034           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/10/2019   | 21/02/2020   | SmPC and PL     |                                                                                                                                            |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10180 /201811 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/06/2019   | 23/08/2019   | SmPC and PL     | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/201811. |
| IAIN/0031/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing | 25/06/2019   | 23/08/2019   | Annex II and PL |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| R/0029              | Renewal of the marketing authorisation.                    | 31/01/2019   | 28/03/2019   | SmPC and Annex II   | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. In this renewal, the CHMP agreed to postpone the due date of the Specific Obligation study, on grounds of the current rate of enrolment, as well as the anticipated time to achieve the required number of PFS events which has implications on the time needed until the primary endpoint can be analysed and results processed. It is therefore acceptable that the due date of the SOB is postponed till 30 September 2020.   |
|---------------------|------------------------------------------------------------|--------------|--------------|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10180 /201711 | Periodic Safety Update EU Single assessment - cabozantinib | 28/06/2018   | 27/08/2018   | SmPC and PL         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10180/201711.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| R/0027              | Renewal of the marketing authorisation.                    | 09/11/2017   | 08/01/2018   | Labelling           | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| PSUSA/10180 /201611   | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                      | 09/06/2017   | n/a        |      | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0026               | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                             | 25/04/2017   | n/a        |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0024               | Update of section 5.3 of the SmPC to reflect the results of the final study report of the non-clinical study (XL184-NC-036) assessing the carcinogenicity potential in rat. In addition, the risk management plan (RMP) is being updated accordingly. The requested variation proposed amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 26/01/2017   | 08/01/2018 | SmPC | The carcinogenic potential of cabozantinib has been evaluated in two species: rasH2 transgenic mice and Sprague-Dawley rats. In the 2-year rat carcinogenicity study, cabozantinib-related neoplastic findings consisted of an increased incidence of benign pheochromocytoma, alone or in combination with malignant pheochromocytoma/complex malignant pheochromocytoma of the adrenal medulla in both sexes at exposures well below the intend exposure in humans. The clinical relevance of the observed neoplastic lesions in rats is uncertain, but likely to be low. |
| R/0022                | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 10/11/2016   | 11/01/2017 |      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion.                                                                                          |
| PSUSA/10180 /201603   | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                      | 13/10/2016   | 12/12/2016 | SmPC | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                                                                                                                                                                                                  |            |            |                        | PSUSA/10180/201603.                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| T/0023              | Marketing authorisation transfer from TMC Pharma Service Limited to Ipsen Pharma. Transfer of Marketing Authorisation                                                                                                                                                                                            | 05/09/2016 | 30/09/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| PSUSA/10180 /201509 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                       | 14/04/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0017              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                          | 19/11/2015 | 11/01/2016 | Annex II               | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligations and Conditions as laid down in Annex II to the Opinion. |
| II/0018             | Update of section 5.3 of the SmPC with the results from the carcinogenicity study in mice. Furthermore, the MAH took the opportunity to align the PI with the latest QRD template version 9.1. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/12/2015 | 30/09/2016 | SmPC                   | In this variation the MAH updated the PI with the information that cabozantinib was not carcinogenic in the rasH2 mouse model at an exposure near the intended human therapeutic exposure.                                                                                                                                                                                                                                                                                         |
| IB/0019             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                   | 04/12/2015 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| PSUSA/10180 /201503   | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/11/2015   | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0015               | Update of sections 4.8 and 5.1 of the SmPC following the results of study XL184-301. The Risk Management Plan version 3 and the Package Leaflet and RMP are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                    | 25/06/2015   | 11/01/2016 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0011/G             | This was an application for a group of variations. Update of sections 4.2 and 5.2 of the SmPC further to the results of studies conducted to assess the pharmacokinetics of cabozantinib in subjects with impaired hepatic and renal function. The PL is proposed to be updated accordingly. The requested group of variations proposed amendments to the Summary of Product Characteristics and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/04/2015   | 27/05/2015 | SmPC and PL | In this group of variations the MAH updated information on dosing in patients with hepatic and renal impairment indicating that in cases of mild or moderate hepatic impairment the recommended dose of cabozantinib needs to be lower than recommended 140 mg (60 mg once daily), while in patients with mild or moderate renal impairment cabozantinib should be used with caution. The medicine is not recommended for use in patients with severe hepatic and renal impairment. |
| II/0013/G             | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/04/2015   | 27/05/2015 | SmPC        | In this variation the MAH provided results from two non-                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | Submission of non-clinical study reports from Enterohepatic recirculation evaluation in dogs (XL184-NC-045) and Enterohepatic recirculation evaluation in rats (XL184-NC-046). The requested group of variations proposed no amendments to the Product Information. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |          | clinical studies evaluating the enterohepatic recirculation, excretion and metabolite profiles of cabozantinib. Based on the results the SmPC has been updated to reflect possibility of drug-drug interactions of cabozantinib and bile salt- sequestering agents such as cholestyramine and cholestagel. Such agents may impact absorption (or reabsorption) resulting in potentially decreased exposure. The clinical significance of these potential interactions is unknown.   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0014             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                               | 14/04/2015 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| PSUSA/10180 /201409 | Periodic Safety Update EU Single assessment - cabozantinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 10/04/2015 | n/a        |          | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0012             | Submission of the final study report from a non- clinical toxicity study of cabozantinib in younger juveniles (XL184-NC-040) C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                        | 26/02/2015 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0009              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 20/11/2014 | 19/01/2015 | SmPC and | The CHMP, having reviewed the available information on                                                                                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     | Annex II   | the status of the fulfilment of Specific Obligation and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Cometriq, subject to the Specific Obligation and Conditions as laid down in Annex II to the Opinion.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0007/G | This was an application for a group of variations. Submission of nonclinical study reports conducted further to CHMP recommendation to perform in vitro experiments to further characterise metabolite M2a (EXEL-1644; 6-desmethyl amide cleavage product sulfate): nonclinical pharmacology study evaluating the on-target kinase inhibition potential of cabozantinib metabolites (Study EXL087); in vitro studies investigating CYP inhibition and drug transporter interactions involving cabozantinib metabolite EXEL-1644 (Studies EXEL1644-NC-006, EXEL1644-NC-007, EXEL1644-NC-008, EXEL1644- NC-010, EXEL1644-NC-011); in vitro metabolism study investigating sulfotransferases involved in the formation of metabolites EXEL-1644 and EXEL-1646 (Study EXEL1644-NC-009). C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered | 18/12/2014 | n/a |            |                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |             | of   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------|
| II/0005/G | This was an application for a group of variations. Update of sections 4.4 and 4.5 of the SmPC with regards to concomitant use with MRP2 inhibitors further to the results of Study XL184-NC-039 evaluating Cabozantinib as a Substrate and Inhibitor of a Panel of Human Drug Transporters (MEA 006). The Package leaflet is updated accordingly; Submission of the results of Study XL184-NC-043 assessing cabozantinib as an inhibitor of human MATE1 and MATE2-K-mediated transport (MEA 007); Submission of the results of Study XL184-NC-048 assessing cabozantinib as an inhibitor of human OAT3, MATE1, and MATE2-K-mediated transport.                                                                                                                             | 18/12/2014 | 27/05/2015 | SmPC and PL |      |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                  |            |            |             |     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----|
| II/0006   | Update of section 4.4 of the SmPC to delete the warning on concomitant use with proton pump inhibitors further to the results of a drug-drug Interaction Study XL184-018 with medicinal products affecting gastric pH (esomeprazole and Famotidine) (MEA 004). The Package leaflet is updated accordingly. The MAH also took the opportunity to make a correction in section 4.5 and the PL. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/09/2014 | 19/01/2015 | SmPC and PL |     |
| II/0004/G | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                  | 25/09/2014 | 19/01/2015 | SmPC        | new |

<div style=\"page-break-after: always\"></div>

|         | data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                              |            |            |                        |                                                  |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------|
| IB/0003 | To extend the shelf-life of the finished product B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)          | 17/06/2014 | 19/01/2015 | SmPC                   | To extend the shelf-life of the finished product |
| IB/0002 | B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes | 28/05/2014 | 19/01/2015 | SmPC, Labelling and PL |                                                  |
| IA/0001 | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                       | 28/04/2014 | 19/01/2015 | SmPC                   |                                                  |